Amarin Corp Plc (AMRN)

[ziploc_1]

Thanks d for posting this from HHS...

"The Committee commends NIH, particularly through NHLBI, for playing an important role in bridging the knowledge gap and en-couraging healthcare professionals and their patients to take actionThe Committee is concerned that, despite these statistics(i.e. R-IT stats), many individuals do not regularly access treatments for residual risk beyond statin therapy. The Committee commends NIH, particularly through NHLBI, for playing an important role in bridging the knowledge gap and en-couraging healthcare professionals and their patients to take action"...

IMO the FDA would have a hard time in in not approving Vascepa for expanded indications.